Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc (ACAD) delivers innovative therapies for central nervous system disorders and rare diseases through targeted research and clinical development. This dedicated news hub provides investors and healthcare professionals with essential updates on ACAD's progress in neurology and neuro-rare disease treatments.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Parkinson's Disease Psychosis therapies, Rett syndrome research advancements, and pipeline progress across ACAD's neuroscience portfolio. Each release maintains scientific rigor while remaining accessible to both medical experts and investment analysts.
Key coverage areas include FDA submissions, peer-reviewed study publications, and collaborative research initiatives. Bookmark this page for centralized access to ACAD's latest scientific achievements and operational updates, carefully vetted for accuracy and relevance to long-term therapeutic development.
Acadia Pharmaceuticals will announce its first quarter financial results on May 8, 2023, after market close. A conference call and webcast will occur on the same day at 4:30 p.m. Eastern Time for discussing these results and company operations. The call will be available on Acadia's website and archived until June 7, 2023. Acadia is recognized for its innovative therapies in neuroscience, particularly for conditions like Parkinson’s disease psychosis and Rett syndrome. The company continues to focus on developing solutions for negative symptoms of schizophrenia and Alzheimer’s-related issues. Investors should note that forward-looking statements regarding future events may contain risks and uncertainties that could affect actual results.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the presentation of four posters at the American Academy of Neurology (AAN) annual meeting from April 22 to 27, 2023, in Boston, Mass. The posters include a secondary analysis of communication-related endpoints from the Phase 3 LAVENDER™ study and an interim analysis of the DAFFODIL™ study. Notable presentations involve real-world physician surveys and an analysis of healthcare resource utilization in Rett syndrome patients. The poster P13 highlights the benefits of Trofinetide compared to placebo in communication abilities among individuals with Rett syndrome, thus showcasing the drug's potential. Rett syndrome is a rare neurological disorder affecting approximately 6,000 to 9,000 patients in the U.S., with Trofinetide being a key treatment option.
Acadia Pharmaceuticals has launched DAYBUE (trofinetide), the first FDA-approved therapy for Rett syndrome, a neurodevelopmental disorder affecting 6,000 to 9,000 patients in the U.S. The drug is available for individuals aged two and older and was officially approved on March 10, 2023. The company emphasizes its commitment to patient support, expanding the Acadia Connect program to enable access to this therapy through financial assistance and prescription support. Notable endorsements from healthcare professionals highlight DAYBUE's potential to improve symptoms and enhance patients' quality of life.
Common side effects include diarrhea (experienced by 85% of patients) and weight loss (12% had losses exceeding 7%). Acadia continues to focus on treatments addressing unmet medical needs in the field of neuroscience.
Acadia Pharmaceuticals (Nasdaq: ACAD) will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 p.m. Eastern Time. The conference will be held virtually, and a live webcast of the presentation can be accessed on the company’s website under the investors section. An archived recording will be available for about one month post-event.
Acadia Pharmaceuticals specializes in advancing neural breakthroughs, having developed the first therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for Rett syndrome. Its clinical efforts are aimed at addressing symptoms of several central nervous system disorders, including schizophrenia and Alzheimer’s disease psychosis.
Acadia Pharmaceuticals has received FDA approval for DAYBUE (trofinetide), the first and only treatment for Rett syndrome affecting 6,000 to 9,000 patients in the U.S. The drug is expected to be available by the end of April 2023.
The approval is supported by the pivotal Phase 3 LAVENDER study, which demonstrated statistically significant improvements in Rett symptoms compared to placebo. Additionally, Acadia received a Rare Pediatric Disease Priority Review Voucher.
Acadia’s CEO stated the approval marks a crucial milestone for patients and families lacking treatment options.
Acadia Pharmaceuticals Inc. reported full-year 2022 net sales of $517.2 million, a 7% increase from 2021, driven by strong demand for NUPLAZID®. The fourth-quarter sales reached $136.5 million, up 4% year-over-year. The company anticipates a transformative 2023, with a PDUFA action date for trofinetide set for March 12, 2023. However, Acadia reported a net loss of $216 million for 2022, increasing from $167.9 million the previous year. For 2023, projected net sales for NUPLAZID are between $520 million to $550 million.
Acadia Pharmaceuticals (NASDAQ: ACAD) will announce its fourth quarter and full year 2022 financial results on
The company will host a conference call and webcast that same day at
Acadia is focused on neuroscience breakthroughs, developing therapies for conditions like Parkinson's disease psychosis, schizophrenia, and Alzheimer's disease psychosis.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
